Enhanced drug metabolism in young children with cystic fibrosis

Archives of Disease in Childhood

Volumn 77, Issue 3, 1997, Pages 239-241

  Parker, A C ^a   Pritchard, P ^a   Preston, T ^b   Smyth, R L ^a   Choonara, I ^a,c  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^b SCOTTISH UNIVERSITIES ENVIRONMENTAL RESEARCH CENTRE   (United Kingdom)

^c DERBYSHIRE CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Caffeine metabolism; Cystic fibrosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BRONCHODILATING AGENT; CAFFEINE; CARBON DIOXIDE; CEFACLOR; CISAPRIDE; CYTOCHROME; CYTOCHROME P 1A2; FLUCLOXACILLIN; GAVISCON; METRONIDAZOLE; NITROFURANTOIN; UNCLASSIFIED DRUG;

ARTICLE; BREATH ANALYSIS; CARBON DIOXIDE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DEMETHYLATION; DRUG METABOLISM; ENZYME BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; MALE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0030748946     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.77.3.239     Document Type: Article

References (18)

1. Isles A, Spino M, Tabachnik E, Levison H, Thiessen J, MacLeod S. Theophylline disposition in cystic fibrosis. Am Rev Respir Dis 1983;127:417-21.
2. Knoppert DC, Spino M, Beck R, Thiessen JJ, MacLeod SM. Cystic fibrosis: Enhanced theophylline metabolism may be linked to the disease. Clin Pharmacol Ther 1988;44: 254-64.
3. Kearns GL, Mallory GB, Crom WR, Evans WE. Enhanced hepatic drug clearance in patients with cystic fibrosis. J Pediatr 1990;117:972-9.
4. Kearns GL. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions. Ann Pharmacother 1993;27:74-9.
5. 2 breath test. Dev Pharmacol Ther 1989;12:90-5.
6. 13C-(N-3-methyl)-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992;52:170-80.
7. Parker AC, Preston T, Heaf D, Kitteringham NR, Choonara I. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br J Clin Pharmacol 1994;38:573-6.
8. Conway SP, Pond MN, Bowler I, et al. The chest radiograph in cystic fibrosis: a new scoring system compared with the Chrispin-Norman and Brasfield scores. Thorax 1994;49: 860-2.
9. 2 breath tests: methodology and fundamental considerations. J Lab Clin Med 1977;90:412-21.
10. Preston T, McMillan DC, Rapid sample throughput for biomedical stable isotope tracer studies. Biomed Environ Mass Spectrom 1988;16:229-35.
11. Craig H. The geochemistry of stable carbon isotopes. Geochim Cosmochim Acta 1957;3:53-92.
12. 2 breath tests as monitors of cytochrome P-450 dependent mixed function mono-oxygenase system in metabolism. In: MacLeod SM, Okey D, Spielberg SP, eds. Developmental pharmacology. New York: Alan R Liss, 1983:119-45.
13. Mazoit J-X, Sandouk P, Zetlaoui P, Scherrman J-M. Pharmacokinetics of unchanged morphine in normal cirrhotic subjects. Anesth Analg 1987;66:293-8.
14. Souich P, McLean AJ, Lalka D, Erill S, Gibaldi M. Pulmonary disease and drug kinetics. Clin Pharmacol 1978;3:257-66.
15. Shepherd RW, Holt TL, Vasques-Velasquez L, Coward WA, Prentic A, Lucas A. Increased energy expenditure in young children with cystic fibrosis. Lancet 1988;i:1300-3.
16. Kearns GL, Crom WR, Karlson KH, Mallory GB, Evans WE. Hepatic drug clearance in patients with mild cystic fibrosis. Clin Pharmacol Ther 1996;59:529-40.
17. Hamelin BA, Xu K, Valle F, Manseau L, Richer M, LeBel M. Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity. Clin Pharmacol Ther 1994;56: 521-9.
18. 2 breath test: dose response and route of N-demethylation in smokers and non-smokers. Clin Pharmacol Ther 1982;32:261-9.